<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05048004</url>
  </required_header>
  <id_info>
    <org_study_id>EA1/215/20</org_study_id>
    <nct_id>NCT05048004</nct_id>
  </id_info>
  <brief_title>Cerebral Embolization During Pulmonary Vein Isolation</brief_title>
  <acronym>TCD-CA</acronym>
  <official_title>Cerebral Embolization During Pulmonary Vein Isolation: an Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the TCD-CA study is to determine the frequency of cerebral embolization during&#xD;
      pulmonary vein isolation using continuous transcranial Doppler examination. Different parts&#xD;
      of the procedure, different ablation techniques and periprocedural anticoagulation regimes&#xD;
      will be compared.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary vein isolation (PVI) is a well-established interventional treatment of patients&#xD;
      with atrial fibrillation. Previous studies have shown that catheter-based treatments such as&#xD;
      PVI may lead to cerebral ischemia. Cerebral ischemia related to PVI may present with new&#xD;
      neurological deficits but may also occur as &quot;silent brain infarction&quot;. However, even &quot;silent&#xD;
      brain infarctions&quot; are associated with an increased risk of incident dementia and clinically&#xD;
      overt new strokes. To date, it remains unclear which procedural steps of PVI are associated&#xD;
      with an increased risk of cerebral ischemia.&#xD;
&#xD;
      Cerebral blood flow and microembolic signals can be detected by using transcranial doppler&#xD;
      ultrasound (TCD). TCD has been used in clinical routine for many years and is known to be&#xD;
      safe in stroke patients. By performing continuous TCD monitoring for microembolic signals&#xD;
      during PVI, the aim of this study is therefore to identify, which procedural steps are&#xD;
      associated with the occurence of cerebral microemboli. In addition, the investigators aim to&#xD;
      compare the frequency of cerebral microemboli in different pulmonary vein isolation&#xD;
      techniques that are applied in clinical routine as well as different periprocedural&#xD;
      anticoagulation regimes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Microembolic Signals (MES)</measure>
    <time_frame>during the procedure</time_frame>
    <description>number of MES detected by transcranial doppler ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>neurological outcome</measure>
    <time_frame>at baseline, 0-5 days after pulmonary vein isolation</time_frame>
    <description>neurological outcome will be evaluated using the National Institute of Health Stroke Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cognitive outcome</measure>
    <time_frame>at baseline, 0-5 days after pulmonary vein isolation</time_frame>
    <description>cognitive outcome will be evaluated using the Montreal Cognitive Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebral infarctions</measure>
    <time_frame>at baseline, 0-5 days after pulmonary vein isolation</time_frame>
    <description>number of new cerebral infarctions on magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebral microbleeds</measure>
    <time_frame>at baseline, 0-5 days after pulmonary vein isolation</time_frame>
    <description>number of new cerebral microbleeds on magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebral macrobleeds</measure>
    <time_frame>at baseline, 0-5 days after pulmonary vein isolation</time_frame>
    <description>number of new cerebral macrobleeds on magnetic resonance imaging</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Ischemic Stroke</condition>
  <condition>Cerebral Microembolism</condition>
  <arm_group>
    <arm_group_label>periprocedural oral anticoagulation</arm_group_label>
    <description>Oral anticoagulation will be continued without a periprocedural pause</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no periprocedural oral anticoagulation</arm_group_label>
    <description>Pause of oral anticoagulation on the day of the intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary Vein Isolation</intervention_name>
    <description>Patients undergoing different forms of pulmonary vein isolation are being monitored for microembolic signals (MES) by transcranial ultrasound. For standard ablation, a Thermocool Smarttouch SF (Biosense Webster) catheter will be used (50 W, target ablation index of 550). For comparison, 35 W on the anterior and 20 W on the posterior left atrium will be used. Furthermore, different periprocedural regimes of oral anticoagulation (continuous vs. minimally interrupted) will be compared.</description>
    <arm_group_label>no periprocedural oral anticoagulation</arm_group_label>
    <arm_group_label>periprocedural oral anticoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        all patients who undergo pulmonary vein isolation as part of their treatment for atrial&#xD;
        fibrillation at Charité-Campus Benjamin Franklin are eligible for study participation.&#xD;
        Clinical indication for the procedure will be established by the treating physician prior&#xD;
        to and irrespective of study participation. Patients who are unable to provide written&#xD;
        informed consent will not be included in this study. Since cerebral MRI prior and after&#xD;
        pulmonary vein isolation is part of the study protocol, patients with contraindications to&#xD;
        cerebral MRI will not be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with atrial fibrillation undergoing catheter-based ablation at Charité-Campus&#xD;
             Benjamin Franklin&#xD;
&#xD;
          -  age 18 years or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  patient unable to provide written informed consent&#xD;
&#xD;
          -  contraindications to cerebral MRI (e.g. pacemaker, mechanic valve implant, cochlea&#xD;
             implant, severe claustrophobia)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian H Nolte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tim B Brämswig, MD</last_name>
    <phone>+4930450560624</phone>
    <email>tim-bastian.braemswig@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Regina von Rennenberg, MD</last_name>
    <phone>+493084454285</phone>
    <email>regina-irene.freiin-von-rennenberg@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité-University Medicine Berlin, Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Tim B Brämswig, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Regina von Rennenberg, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Christian H Nolte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Huemer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Attanasio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Verena Tscholl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tobias Schreiber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Christian Nolte</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

